small molecule

JASCAYD

NERANDOMILAST

Loss of exclusivityOctober 2038latest FDA-listed patent expiry

CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand name	JASCAYD
Active ingredient	NERANDOMILAST
Strength	18MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11813266	October 2038	use U-4292
11406638	October 2038	use U-4297
9802954	February 2034	use U-4298
8609670	August 2032	substance
8754073	November 2029	substance, product

Regulatory exclusivity

Code	Expires
ODE-546	October 2032
NCE	October 2030
I-979	December 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Boehringer Ingelheim